| Ryan Sacksteder, OD | |
|
148 13th St Sw, Largo, FL 33770-3127 | |
| (727) 581-8706 | |
| (727) 586-3743 |
| Full Name | Ryan Sacksteder |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 12 Years |
| Location | 148 13th St Sw, Largo, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265780555 | NPI | - | NPPES |
| 006480900 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | OPC4734 (Florida) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Eye Physicians Of Pinellas, Pa | 5092629071 | 37 |
News Archive
Researchers from the University of Exeter in England have found that cancer patients are being mislead by many popular health web sites providing bogus information to peddle alternative medicinal treatments.
Women with ductal carcinoma in situ-DCIS-who later develop invasive breast cancer in the same breast are at higher risk of dying from breast cancer than those who do not develop invasive disease, according to a study published online March 11 in the Journal of the National Cancer Institute.
Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone.
The National Endowment for Humanities (NEH) has awarded a Challenge Grant to The Center for the History and Ethics of Public Health at Columbia University's Mailman School of Public Health.
› Verified 9 days ago
| Provider Name | The Eye Physicians Of Pinellas, Pa |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1114925153 PECOS PAC ID: 5092629071 Enrollment ID: O20040507000828 |
News Archive
Researchers from the University of Exeter in England have found that cancer patients are being mislead by many popular health web sites providing bogus information to peddle alternative medicinal treatments.
Women with ductal carcinoma in situ-DCIS-who later develop invasive breast cancer in the same breast are at higher risk of dying from breast cancer than those who do not develop invasive disease, according to a study published online March 11 in the Journal of the National Cancer Institute.
Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone.
The National Endowment for Humanities (NEH) has awarded a Challenge Grant to The Center for the History and Ethics of Public Health at Columbia University's Mailman School of Public Health.
› Verified 9 days ago
| Provider Name | Gulf Coast Optometry Pa |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1083859409 PECOS PAC ID: 0941359533 Enrollment ID: O20090602000109 |
News Archive
Researchers from the University of Exeter in England have found that cancer patients are being mislead by many popular health web sites providing bogus information to peddle alternative medicinal treatments.
Women with ductal carcinoma in situ-DCIS-who later develop invasive breast cancer in the same breast are at higher risk of dying from breast cancer than those who do not develop invasive disease, according to a study published online March 11 in the Journal of the National Cancer Institute.
Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone.
The National Endowment for Humanities (NEH) has awarded a Challenge Grant to The Center for the History and Ethics of Public Health at Columbia University's Mailman School of Public Health.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ryan Sacksteder, OD 148 13th St Sw, Largo, FL 33770-3127 Ph: (727) 581-8706 | Ryan Sacksteder, OD 148 13th St Sw, Largo, FL 33770-3127 Ph: (727) 581-8706 |
News Archive
Researchers from the University of Exeter in England have found that cancer patients are being mislead by many popular health web sites providing bogus information to peddle alternative medicinal treatments.
Women with ductal carcinoma in situ-DCIS-who later develop invasive breast cancer in the same breast are at higher risk of dying from breast cancer than those who do not develop invasive disease, according to a study published online March 11 in the Journal of the National Cancer Institute.
Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone.
The National Endowment for Humanities (NEH) has awarded a Challenge Grant to The Center for the History and Ethics of Public Health at Columbia University's Mailman School of Public Health.
› Verified 9 days ago
Dr. Victoria Huynh, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1030 W Bay Dr, Largo, FL 33770 Phone: 727-585-2200 Fax: 727-584-9239 | |
Dr. David Anderson, OD Optometrist Medicare: Medicare Enrolled Practice Location: 800 E Bay Dr Ste G, Largo, FL 33770 Phone: 727-584-1893 Fax: 727-584-1973 | |
Dr. Ronald Gene Tucker, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 800 E Bay Dr, Suite G, Largo, FL 33770 Phone: 727-584-1893 Fax: 727-584-1973 | |
Francis Barreiro Od Pa Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1915 E Bay Dr, Suite A-3, Largo, FL 33771 Phone: 727-584-1508 | |
Ronald G Tucker Od Pa Optometrist Medicare: Not Enrolled in Medicare Practice Location: 800 E Bay Dr, Suite G, Largo, FL 33770 Phone: 727-584-1893 Fax: 727-584-1973 | |
Dr. Korey Andrew Young, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 10500 Ulmerton Rd, Ste 230, Largo, FL 33771 Phone: 727-585-8600 Fax: 727-585-4205 | |
Dr. Jeffery D Laplume, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 800 E Bay Dr Ste G, Largo, FL 33770 Phone: 727-584-1893 |